

Roberta Joppi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6742985/publications.pdf>

Version: 2024-02-01

9
papers

450
citations

1163117
8
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

570
citing authors

#	ARTICLE	IF	CITATIONS
1	Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 170-174.	2.4	16
2	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	2.7	102
3	A disease looking for innovative drugs: The case of pulmonary arterial hypertension. <i>European Journal of Internal Medicine</i> , 2018, 55, 47-51.	2.2	3
4	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017, 8, 497.	3.5	34
5	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , 2016, 7, 305.	3.5	48
6	Letting post-marketing bridge the evidence gap: the case of orphan drugs: Table 1. <i>BMJ, The</i> , 2016, 353, i2978.	6.0	36
7	Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1009-1024.	1.9	90
8	Orphan drug development is not taking off. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 494-502.	2.4	57
9	Orphan drug development is progressing too slowly. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 355-360.	2.4	64